- United States
- /
- Healthtech
- /
- NYSE:PHR
Even though Phreesia (NYSE:PHR) has lost US$99m market cap in last 7 days, shareholders are still up 41% over 3 years
While Phreesia, Inc. (NYSE:PHR) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 14% in the last quarter. On the other hand the share price is higher than it was three years ago. Arguably you'd have been better off buying an index fund, because the gain of 41% in three years isn't amazing.
Although Phreesia has shed US$99m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.
Our free stock report includes 1 warning sign investors should be aware of before investing in Phreesia. Read for free now.Because Phreesia made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Over the last three years Phreesia has grown its revenue at 22% annually. That's much better than most loss-making companies. While long-term shareholders have made money, the 12% per year gain over three years isn't that great given the rising market. We would have thought the top-line growth might have impressed buyers more. It could be that the stock was previously over-priced, or its losses might worry the market. But you might want to take a closer look at this one.
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
Phreesia is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So it makes a lot of sense to check out what analysts think Phreesia will earn in the future (free analyst consensus estimates)
A Different Perspective
Phreesia shareholders are up 7.9% for the year. Unfortunately this falls short of the market return. But at least that's still a gain! Over five years the TSR has been a reduction of 3% per year, over five years. It could well be that the business is stabilizing. It's always interesting to track share price performance over the longer term. But to understand Phreesia better, we need to consider many other factors. For example, we've discovered 1 warning sign for Phreesia that you should be aware of before investing here.
We will like Phreesia better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:PHR
Phreesia
Provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.
Undervalued with adequate balance sheet.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves
The First Real Lidar Winner

The Most Wonderful Monopoly in the Most Dangerous Neighbourhood on Earth
Recently Updated Narratives

Renewed focus on business investment
Nova Ljubljanska Banka d.d. future looks bright with a profit margin change of 38%
Fibromat: More than just a niche player, with clearer earnings visibility from order book and project wins
Popular Narratives

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

The academically fascinating Tesla

